Lupin to Divest its Stake in Kyowa to Unison for ~$525M
Shots:
- Lupin’s subsidiary Nanomi to sell its entire stake (99.82%) in Kyowa to Unison’s entity Plutus in an all-cash transaction for an enterprise value of ~$525.87M and will generate post-tax net cash inflow of ~$300M. The transfer is expected to be completed in Mar’2020
- The divestiture will strengthen Lupin’s balance sheet and its growth capital to support organic and inorganic initiatives- allowing it to focus on key markets
- Kyowa in collaboration with Unison will provide various solutions beyond the pharmaceutical business by leveraging its strong position in CNS generics- longlisted and specialty products with Unison’s investments in healthcare- forming a leading CNS company
Click here- Click here to read full press release/ article | Ref: Lupin- Kyowa | Image: Business Standard
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com